Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data.
Ewing sarcoma is the second most common type of bone cancer in children and young adults. In recent years, the mechanisms by which these tumors develop and maintain their vascular supply have been elucidated. Additional work has demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of Ewing sarcoma mouse xenografts. Early clinical data suggest that these results also may extend to patients with Ewing sarcoma who are treated with antiangiogenic or antivascular therapies. For the current review, the authors summarized the available data supporting this approach.
DuBois
Steven G
SG
Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143-0106, USA. duboiss@peds.ucsf.edu
Marina
Neyssa
N
Glade-Bender
Julia
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D012512:Sarcoma, Ewing / Q000098:blood supply* / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors